SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $75 to $78.
‘A Federal Appeals Court In San Francisco Has Rejected Apple’s $310M Settlement Of Claims That The Tech Giant Disguised Certain iphone Battery Defects By Throttling Their System Performance’ – Bloomberg Law
https://news.bloomberglaw.com/product-liability-and-toxics-law/apples-310-million-iphone-settlement-rejected-by-appeals-court?context=search&index=0&campaign=1597FE56-3F52-11ED-B81D-F3C34F017A06&utm_source=tw